On the role of Y chromosome loss in malignancies: the driving mechanisms and potentials in precision oncology
Received date: 2025-12-20
Revised date: 2026-02-25
Online published: 2026-04-29
Supported by
National Natural Science Foundation of China(32260148);National Natural Science Foundation of China(31900410);Xing Dian Plan “Youth Talent Program” of Yunnan Province
Biological sex is a critical determinant influencing the incidence, progression, clinical presentation, and prognosis of human diseases. Beyond sex-specific tumors, men typically exhibit higher morbidity and mortality rates in nearly all tumors compared to women. However, the genetic mechanisms underlying the cancer sex bias are not definitive. Loss of Y chromosome (LOY), the most prevalent somatic mutation in healthy males, frequently occurs in individuals over 50 years of age. On one hand, LOY in peripheral blood immune cells is strongly associated with increased tumor susceptibility. On the other hand, LOY also frequently occurs within tumor cells themselves, leading to the loss of Y-chromosome-linked tumor suppressor genes and non-coding RNAs, thereby reshaping the tumor microenvironment through mechanisms such as metabolic reprogramming and altering tumor immunity. Strikingly, LOY is a “contagious” mutation, which means malignant cells with LOY cause the same mutation in tumor-infiltrating immune cells, and the synergistic interaction between two types of LOY cells accelerates tumor evolution. Given the widespread occurrence of LOY in tumors and its crucial role in malignant progression, LOY holds great promise as a biomarker for early diagnosis, classification, and staging, as well as a potential target for precision therapy. Here, we summarize the mechanisms by which LOY drives malignant progression in solid tumors from the perspectives of tumor-cell-intrinsic LOY, LOY in tumor-infiltrating immune cells, and their crosstalk. We also discuss the developmental opportunities and translational potential of LOY in precision oncology. This review aims to provide novel insights into the molecular basis of sex disparities in tumors and to identify potential molecular targets for precision prevention, diagnosis, and treatment.
Key words： loss of Y chromosome; tumor; tumor immunity; immunotherapy; precision oncology
Jiazhi Su, Lina Zhu, Xue Chen, Xu Wang, Xihan Guo . On the role of Y chromosome loss in malignancies: the driving mechanisms and potentials in precision oncology[J]. Hereditas(Beijing), 2026 , 48(8) : 781 -795 . DOI: 10.16288/j.yczz.25-329
| [1] | Zheng DS, Trynda J, Williams C, Vold JA, Nguyen JH, Harnois DM, Bagaria SP, McLaughlin SA, Li ZY. Sexual dimorphism in the incidence of human cancers. BMC Cancer, 2019, 19(1): 684. |
| [2] | Massey SC, Whitmire P, Doyle TE, Ippolito JE, Mrugala MM, Hu LS, Canoll P, Anderson ARA, Wilson MA, Fitzpatrick SM, McCarthy MM, Rubin JB, Swanson KR. Sex differences in health and disease: a review of biological sex differences relevant to cancer with a spotlight on glioma. Cancer Lett, 2021, 498: 178-187. |
| [3] | Edgren G, Liang LM, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol, 2012, 27(3): 187-196. |
| [4] | Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev, 2011, 20(8): 1629-1637. |
| [5] | Jackson SS, Marks MA, Katki HA, Cook MB, Hyun N, Freedman ND, Kahle LL, Castle PE, Graubard BI, Chaturvedi AK. Sex disparities in the incidence of 21 cancer types: quantification of the contribution of risk factors. Cancer, 2022, 128(19): 3531-3540. |
| [6] | Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, Arredouani MS. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci USA, 2014, 111(27): 9887-9892. |
| [7] | Kwon H, Schafer JM, Song NJ, Kaneko S, Li AQ, Xiao T, Ma AJ, Allen C, Das K, Zhou L, Riesenberg B, Chang YZ, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung DJ, Li X, Li ZH. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol, 2022, 7(73): eabq2630. |
| [8] | Guan XN, Polesso F, Wang CJ, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, Hipfinger C, Hammond SA, Graff JN, Xia Z, Moran AE. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature, 2022, 606(7915): 791-796. |
| [9] | Guo XH, Dai XQ, Zhou T, Wang H, Ni J, Xue JL, Wang X. Mosaic loss of human Y chromosome: what, how and why. Hum Genet, 2020, 139(4): 421-446. |
| [10] | Rhie A, Nurk S, Cechova M, Hoyt SJ, Taylor DJ, Altemose N, Hook PW, Koren S, Rautiainen M, Alexandrov IA, Allen J, Asri M, Bzikadze AV, Chen NC, Chin CS, Diekhans M, Flicek P, Formenti G, Fungtammasan A, Garcia Giron C, Garrison E, Gershman A, Gerton JL, Grady PGS, Guarracino A, Haggerty L, Halabian R, Hansen NF, Harris R, Hartley GA, Harvey WT, Haukness M, Heinz J, Hourlier T, Hubley RM, Hunt SE, Hwang S, Jain M, Kesharwani RK, Lewis AP, Li H, Logsdon GA, Lucas JK, Makalowski W, Markovic C, Martin FJ, Mc Cartney AM, McCoy RC, McDaniel J, McNulty BM, Medvedev P, Mikheenko A, Munson KM, Murphy TD, Olsen HE, Olson ND, Paulin LF, Porubsky D, Potapova T, Ryabov F, Salzberg SL, Sauria MEG, Sedlazeck FJ, Shafin K, Shepelev VA, Shumate A, Storer JM, Surapaneni L, Taravella Oill AM, Thibaud-Nissen F, Timp W, Tomaszkiewicz M, Vollger MR, Walenz BP, Watwood AC, Weissensteiner MH, Wenger AM, Wilson MA, Zarate S, Zhu YM, Zook JM, Eichler EE, O'Neill RJ, Schatz MC, Miga KH, Makova KD, Phillippy AM. The complete sequence of a human Y chromosome. Nature, 2023, 621(7978): 344-354. |
| [11] | Jobling MA, Tyler-Smith C. Human Y-chromosome variation in the genome-sequencing era. Nat Rev Genet, 2017, 18(8): 485-497. |
| [12] | Maan AA, Eales J, Akbarov A, Rowland J, Xu XG, Jobling MA, Charchar FJ, Tomaszewski M. The Y chromosome: a blueprint for men’s health? Eur J Hum Genet, 2017, 25(11): 1181-1188. |
| [13] | Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG, Repping S, Pyntikova T, Ali J, Bieri T, Chinwalla A, Delehaunty A, Delehaunty K, Du H, Fewell G, Fulton L, Fulton R, Graves T, Hou SF, Latrielle P, Leonard S, Mardis E, Maupin R, McPherson J, Miner T, Nash W, Nguyen C, Ozersky P, Pepin K, Rock S, Rohlfing T, Scott K, Schultz B, Strong C, Tin-Wollam A, Yang SP, Waterston RH, Wilson RK, Rozen S, Page DC. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature, 2003, 423(6942): 825-837. |
| [14] | Jacobs PA, Court Brown W, Doll R. Distribution of human chromosome counts in relation to age. Nature, 1961, 191: 1178-1180. |
| [15] | Jacobs PA, Brunton M, Court Brown W, Doll R, Goldstein H. Change of human chromosome count distribution with age: evidence for a sex differences. Nature, 1963, 197: 1080-1081. |
| [16] | Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, de Ståhl TD, Zaghlool A, Giedraitis V, Lannfelt L, Score J, Cross NCP, Absher D, Janson ET, Lindgren CM, Morris AP, Ingelsson E, Lind L, Dumanski JP. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet, 2014, 46(6): 624-628. |
| [17] | Loftfield E, Zhou WY, Yeager M, Chanock SJ, Freedman ND, Machiela MJ. Mosaic Y loss is moderately associated with solid tumor risk. Cancer Res, 2019, 79(3): 461-466. |
| [18] | Dumanski JP, Halvardson J, Davies H, Rychlicka- Buniowska E, Mattisson J, Moghadam BT, Nagy N, Węglarczyk K, Bukowska-Strakova K, Danielsson M, Olszewski P, Piotrowski A, Oerton E, Ambicka A, Przewoźnik M, Bełch Ł, Grodzicki T, Chłosta PL, Imreh S, Giedraitis V, Kilander L, Nordlund J, Ameur A, Gyllensten U, Johansson Å, Józkowicz A, Siedlar M, Klich-Rączka A, Jaszczyński J, Enroth S, Baran J, Ingelsson M, Perry JRB, Ryś J, Forsberg LA. Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cell Mol Life Sci, 2021, 78(8): 4019-4033. |
| [19] | Noveski P, Madjunkova S, Sukarova Stefanovska E, Matevska Geshkovska N, Kuzmanovska M, Dimovski A, Plaseska-Karanfilska D. Loss of Y chromosome in peripheral blood of colorectal and prostate cancer patients. PLoS One, 2016, 11(1): e0146264. |
| [20] | Kobayashi T, Hachiya T, Ikehata Y, Horie S. Genetic association of mosaic loss of chromosome Y with prostate cancer in men of European and East Asian ancestries: a Mendelian randomization study. Front Aging, 2023, 4(1): 1176451. |
| [21] | Qin N, Li N, Wang C, Pu ZN, Ma ZJ, Jin GF, Zhu M, Dai M, Hu ZB, Ma HX. Association of mosaic loss of chromosome Y with lung cancer risk and prognosis in a Chinese population. J Thorac Oncol, 2019, 14(1): 37-44. |
| [22] | Zhu LN, Wang X, Guo XH. Hematopoietic mosaic loss of Y chromosome: from population cohorts to pathogenic mechanisms. Hereditas(Beijing), 2025, 47(4): 409-427. |
| 朱丽娜, 汪旭, 郭锡汉. 造血系统嵌合型Y染色体丢失: 从人群队列到致病机制. 遗传, 2025, 47(4): 409-427. | |
| [23] | Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. |
| [24] | Dong M, Cioffi G, Wang J, Waite KA, Ostrom QT, Kruchko C, Lathia JD, Rubin JB, Berens ME, Connor J, Barnholtz-Sloan JS. Sex differences in cancer incidence and survival: a pan-cancer analysis. Cancer Epidemiol Biomarkers Prev, 2020, 29(7): 1389-1397. |
| [25] | He Y, Su YL, Zeng JS, Chong W, Hu XL, Zhang Y, Peng XC. Cancer-specific survival after diagnosis in men versus women: a pan-cancer analysis. MedComm (2020), 2022, 3(3): e145. |
| [26] | Chen XY, Shen YL, Choi S, Abdel-Hafiz HA, Basu M, Hoelzen L, Tufano M, Kailasam Mani SK, Ranjpour M, Zhu JN, Ramanujan VK, Koltsova EK, Calsavara VF, Knott SRV, Theodorescu D. Concurrent loss of the Y chromosome in cancer and T cells impacts outcome. Nature, 2025, 642(8069): 1041-1050. |
| [27] | Abdel-Hafiz HA, Schafer JM, Chen XY, Xiao T, Gauntner TD, Li ZH, Theodorescu D. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature, 2023, 619(7970): 624-631. |
| [28] | Qi MF, Pang JL, Mitsiades I, Lane AA, Rheinbay E. Loss of chromosome Y in primary tumors. Cell, 2023, 186(14): 3125-3136. |
| [29] | Müller P, Camacho OV, Yazbeck AM, Wölwer C, Zhai WW, Schumacher J, Heider D, Buettner R, Quaas A, Hillmer AM. Why loss of Y? A pan-cancer genome analysis of tumors with loss of Y chromosome. Comput Struct Biotechnol J, 2023, 21: 1573-1583. |
| [30] | Arseneault M, Monlong J, Vasudev NS, Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N, Panichnantakul P, Holcatova I, Brisuda A, Janout V, Kollarova H, Foretova L, Navratilova M, Mates D, Jinga V, Zaridze D, Mukeria A, Jandaghi P, Brennan P, Brazma A, Tost J, Scelo G, Banks RE, Lathrop M, Bourque G, Riazalhosseini Y. Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. Sci Rep, 2017, 7(1): 44876. |
| [31] | Hollows R, Wei WB, Cazier JB, Mehanna H, Parry G, Halford G, Murray P. Association between loss of Y chromosome and poor prognosis in male head and neck squamous cell carcinoma. Head Neck, 2019, 41(4): 993-1006. |
| [32] | Cáceres A, Jene A, Esko T, Perez-Jurado LA, Gonzalez JR. Extreme downregulation of chromosome Y and cancer risk in men. J Natl Cancer Inst, 2020, 112(9): 913-920. |
| [33] | Zhang Q, Zhao L, Yang Y, Li SJ, Liu Y, Chen C. Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis. JCI Insight, 2022, 7(3): e153768. |
| [34] | Willis-Owen SAG, Domingo-Sabugo C, Starren E, Liang LM, Freidin MB, Arseneault M, Zhang YM, Lu SK, Popat S, Lim E, Nicholson AG, Riazalhosseini Y, Lathrop M, Cookson WOC, Moffatt MF. Y disruption, autosomal hypomethylation and poor male lung cancer survival. Sci Rep, 2021, 11(1): 12453. |
| [35] | Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GSM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest, 2018, 128(7): 2979-2995. |
| [36] | Li JX, Lan ZD, Liao WT, Horner JW, Xu XP, Liu JL, Yoshihama Y, Jiang S, Shim HS, Slotnik M, LaBella KA, Wu CJ, Dunner K Jr, Hsu WH, Lee R, Khanduri I, Terranova C, Akdemir K, Chakravarti D, Shang XY, Spring DJ, Wang YA, DePinho RA. Histone demethylase KDM5D upregulation drives sex differences in colon cancer. Nature, 2023, 619(7970): 632-639. |
| [37] | Grillone K, Riillo C, Scionti F, Rocca R, Tradigo G, Guzzi PH, Alcaro S, Di Martino MT, Tagliaferri P, Tassone P. Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”. J Exp Clin Cancer Res, 2020, 39(1): 117. |
| [38] | Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell, 2019, 179(5): 1033-1055. |
| [39] | Wu SJ, Wu YW, Deng SJ, Lei XY, Yang XY. Emerging roles of noncoding RNAs in human cancers. Discov Oncol, 2023, 14(1): 128. |
| [40] | Chen BQ, Dragomir MP, Yang C, Li QQ, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther, 2022, 7(1): 121. |
| [41] | Ma DN, Gao XY, Liu Z, Lu XG, Ju HX, Zhang N. Exosome-transferred long non-coding RNA ASMTL- AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Cell Prolif, 2020, 53(9): e12795. |
| [42] | Liang WJ, Wang Y, Zhang QY, Gao M, Zhou HZ, Wang ZR. m6A-mediated upregulation of LINC00106 promotes stemness and metastasis properties of hepatocellular carcinoma via sponging let7f. Front Cell Dev Biol, 2021, 9: 781867. |
| [43] | Xiao GA, Yao JJ, Kong DP, Ye C, Chen R, Li L, Zeng T, Wang LJ, Zhang W, Shi XL, Zhou T, Li J, Wang Y, Xu CL, Jiang JF, Sun YH. The long noncoding RNA TTTY15, which is located on the Y chromosome, promotes prostate cancer progression by sponging let-7. Eur Urol, 2019, 76(3): 315-326. |
| [44] | Wang W, Yang JB. Long noncoding RNA TTTY15 promotes growth and metastasis of esophageal squamous cell carcinoma by sponging microRNA-337-3p to upregulate the expression of JAK2. Anticancer Drugs, 2020, 31(10): 1038-1045. |
| [45] | Wen XG, Han WL, Liu C. Long non-coding RNA TTTY15 silencing inhibits gastric cancer progression by sponging microRNA-98-5p to down-regulate cyclin D2 expression. Bioengineered, 2022, 13(3): 7380-7391. |
| [46] | Wu SQ, Zhang LY, Deng JQ, Guo BB, Li F, Wang YR, Wu R, Zhang SH, Lu JC, Zhou YF. A novel micropeptide encoded by Y-linked LINC00278 links cigarette smoking and AR signaling in male esophageal squamous cell carcinoma. Cancer Res, 2020, 80(13): 2790-2803. |
| [47] | Lai IL, Chang YS, Chan WL, Lee YT, Yen JC, Yang CA, Hung SY, Chang JG. Male-specific long noncoding RNA TTTY15 inhibits non-small cell lung cancer proliferation and metastasis via TBX4. Int J Mol Sci, 2019, 20(14): 3473. |
| [48] | Brownmiller T, Juric JA, Ivey AD, Harvey BM, Westemeier ES, Winters MT, Stevens AM, Stanley AN, Hayes KE, Sprowls SA, Ammer ASG, Walker M, Bey EA, Wu XL, Lim ZF, Zhu L, Wen SJ, Hu GQ, Ma PC, Martinez I. Y chromosome lncRNA are involved in radiation response of male non-small cell lung cancer cells. Cancer Res, 2020, 80(19): 4046-4057. |
| [49] | Westemeier-Rice ES, Winters MT, Rawson TW, Patel KJ, McHugh O, Ward S, McLaughlin S, Stewart A, Misra B, Dziadowicz S, Yi WJ, Bobbala S, Hu GQ, Martinez I. Lnc-RAINY regulates genes involved in radiation susceptibility through DNA: DNA: RNA triplex-forming interactions and has tumor therapeutic potential in lung cancers. Noncoding RNA Res, 2025, 12: 152-166. |
| [50] | Fischer J, Shutta KH, Chen C, Fanfani V, Saha E, Mandros P, Guebila MB, Xiu J, Nieva J, Liu S, Uprety D, Spetzler D, Lopes-Ramos CM, DeMeo DL, Quackenbush J. Selective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens. bioRxiv, 2025, doi: 10.1101/2024.09.19.613876. |
| [51] | Subramaniyan B, Acharya BR, Anand P, Mani SKK, Mohapatra S, Chen XY, Qu FY, Fstkchyan Y, Gutierrez C, Abdel-Hafiz H, Costello J, Theodorescu D. Loss of the Y chromosome drives cancer metabolic reprogramming. bioRxiv, 2025, doi: 10.1101/2025.08.26.672471. |
| [52] | Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol, 2020, 38(1): 541-566. |
| [53] | Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res, 2017, 27: 109-118. |
| [54] | Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, Davidsson OB, Day FR, Sulem P, Jiang YX, Danielsson M, Davies H, Dennis J, Dunlop MG, Easton DF, Fisher VA, Zink F, Houlston RS, Ingelsson M, Kar S, Kerrison ND, Kinnersley B, Kristjansson RP, Law PJ, Li R, Loveday C, Mattisson J, McCarroll SA, Murakami Y, Murray A, Olszewski P, Rychlicka- Buniowska E, Scott RA, Thorsteinsdottir U, Tomlinson I, Moghadam BT, Turnbull C, Wareham NJ, Gudbjartsson DF, International Lung Cancer Consortium (INTEGRAL- ILCCO), Breast Cancer Association Consortium, Consortium of Investigators of Modifiers of BRCA1/2, Endometrial Cancer Association Consortium, Ovarian Cancer Association Consortium, Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium, Kidney Cancer GWAS Meta-Analysis Project, eQTLGen Consortium, Biobank-based Integrative Omics Study (BIOS) Consortium, 23andMe Research Team, Kamatani Y, Hoffmann ER, Jackson SP, Stefansson K, Auton A, Ong KK, Machiela MJ, Loh PR, Dumanski JP, Chanock SJ, Forsberg LA, Perry JRB. Genetic predisposition to mosaic Y chromosome loss in blood. Nature, 2019, 575(7784): 652-657. |
| [55] | Mattisson J, Danielsson M, Hammond M, Davies H, Gallant CJ, Nordlund J, Raine A, Edén M, Kilander L, Ingelsson M, Dumanski JP, Halvardson J, Forsberg LA. Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. Sci Rep, 2021, 11(1): 15160. |
| [56] | Wójcik M, Juhas U, Mohammadi E, Mattisson J, Drężek-Chyła K, Rychlicka-Buniowska E, Bruhn- Olszewska B, Davies H, Chojnowska K, Olszewski P, Bieńkowski M, Jankowski M, Rostkowska O, Hellmann A, Pęksa R, Kowalski J, Zdrenka M, Kobiela J, Zegarski W, Biernat W, Szylberg Ł, Remiszewski P, Mieczkowski J, Filipowicz N, Dumanski JP. Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases. Sci Rep, 2024, 14(1): 9458. |
| [57] | Mattisson J, Halvardson J, Davies H, Bruhn-Olszewska B, Olszewski P, Danielsson M, Bjurling J, Lindberg A, Zaghlool A, Rychlicka-Buniowska E, Dumanski JP, Forsberg LA. Loss of chromosome Y in regulatory T cells. BMC Genomics, 2024, 25(1): 243. |
| [58] | Danielsson M, Halvardson J, Davies H, Torabi Moghadam B, Mattisson J, Rychlicka-Buniowska E, Jaszczyński J, Heintz J, Lannfelt L, Giedraitis V, Ingelsson M, Dumanski JP, Forsberg LA. Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals. Eur J Hum Genet, 2020, 28(3): 349-357. |
| [59] | Duan QC, Gao YR, Cao XX, Wang SL, Xu MM, Jones OD, Xu XH. Mosaic loss of chromosome Y in peripheral blood cells is associated with age-related macular degeneration in men. Cell Biosci, 2022, 12(1): 73. |
| [60] | “中国学科及前沿领域发展战略研究(2021-2035)”项目组编. 中国精准医学2035发展战略. 北京: 科学出版社, 2023, 1-300. |
| [61] | Guo XH, Li JF, Xue JL, Fenech M, Wang X. Loss of Y chromosome: an emerging next-generation biomarker for disease prediction and early detection? Mutat Res Rev Mutat Res, 2021, 788: 108389. |
| [62] | Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, Antillon MR. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol, 2008, 14(10): 1479-1490. |
| [63] | Van Vliet EPM, Heijenbrok-Kal MH, Hunink MGM, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer, 2008, 98(3): 547-557. |
| [64] | Russell IT, Edwards RT, Gliddon AE, Ingledew DK, Russell D, Whitaker R, Yeo ST, Attwood SE, Barr H, Nanthakumaran S, Park KGM. Cancer of oesophagus or gastricus-new assessment of technology of endosonography (COGNATE): report of pragmatic randomised trial. Health Technol Assess, 2013, 17(39): 1-170. |
| [65] | Raters VM, Gebauer F, Löser H, Schröder W, Schlösser HA, Fuchs H, Bruns C, Quaas A, Zander T. Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma. Front Oncol, 2023, 13: 1249172. |
| [66] | Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, Ahmed R. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med, 2018, 69(1): 301-318. |
| [67] | Cortez D, Marin R, Toledo-Flores D, Froidevaux L, Liechti A, Waters PD, Grützner F, Kaessmann H. Origins and functional evolution of Y chromosomes across mammals. Nature, 2014, 508(7497): 488-493. |
| [68] | Wallis MC, Waters PD, Graves JAM. Sex determination in mammals-before and after the evolution of SRY. Cell Mol Life Sci, 2008, 65(20): 3182-3195. |
| [69] | Mueller JL, Skaletsky H, Brown LG, Zaghlul S, Rock S, Graves T, Auger K, Warren WC, Wilson RK, Page DC. Independent specialization of the human and mouse X chromosomes for the male germ line. Nat Genet, 2013, 45(9): 1083-1087. |
| [70] | Bellott DW, Skaletsky H, Pyntikova T, Mardis ER, Graves T, Kremitzki C, Brown LG, Rozen S, Warren WC, Wilson RK, Page DC. Convergent evolution of chicken Z and human X chromosomes by expansion and gene acquisition. Nature, 2010, 466(7306): 612-616. |
| [71] | Bellott DW, Hughes JF, Skaletsky H, Brown LG, Pyntikova T, Cho TJ, Koutseva N, Zaghlul S, Graves T, Rock S, Kremitzki C, Fulton RS, Dugan S, Ding Y, Morton D, Khan Z, Lewis L, Buhay C, Wang QY, Watt J, Holder M, Lee S, Nazareth L, Alföldi J, Rozen S, Muzny DM, Warren WC, Gibbs RA, Wilson RK, Page DC. Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature, 2014, 508(7497): 494-499. |
| [72] | Patmore DM, Jassim A, Nathan E, Gilbertson RJ, Tahan D, Hoffmann N, Tong YA, Smith KS, Kanneganti TD, Suzuki H, Taylor MD, Northcott P, Gilbertson RJ. DDX3X suppresses the susceptibility of hindbrain lineages to medulloblastoma. Dev Cell, 2020, 54(4): 455-470. |
| [73] | Wang L, Shilatifard A. UTX mutations in human cancer. Cancer Cell, 2019, 35(2): 168-176. |
| [74] | San Roman AK, Godfrey AK, Skaletsky H, Bellott DW, Groff AF, Harris HL, Blanton LV, Hughes JF, Brown L, Phou S, Buscetta A, Kruszka P, Banks N, Dutra A, Pak E, Lasutschinkow PC, Keen C, Davis SM, Tartaglia NR, Samango-Sprouse C, Muenke M, Page DC. The human inactive X chromosome modulates expression of the active X chromosome. Cell Genom, 2023, 3(2): 100259. |
| [75] | Köferle A, Schlattl A, Hörmann A, Thatikonda V, Popa A, Spreitzer F, Ravichandran MC, Supper V, Oberndorfer S, Puchner T, Wieshofer C, Corcokovic M, Reiser C, Wöhrle S, Popow J, Pearson M, Martinez J, Weitzer S, Mair B, Neumüller RA. Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. Cell Rep, 2022, 39(2): 110636. |
| [76] | Gherardini L, Inzalaco G, Imperatore F, D’Aurizio R, Franci L, Miragliotta V, Boccuto A, Calandro P, Andreini M, Tarditi A, Chiariello M. The FHP01 DDX3X helicase inhibitor exerts potent anti-tumor activity in vivo in breast cancer pre-clinical models. Cancers (Basel), 2021, 13(19): 4830. |
| [77] | Nakao S, Nogami M, Iwatani M, Imaeda T, Ito M, Tanaka T, Tawada M, Endo S, Cary DR, Ohori M, Imaeda Y, Kawamoto T, Aparicio S, Nakanishi A, Araki S. Identification of a selective DDX3X inhibitor with newly developed quantitative high-throughput RNA helicase assays. Biochem Biophys Res Commun, 2020, 523(3): 795-801. |
| [78] | Xu J, Peng XX, Chen YX, Zhang YZ, Ma Q, Liang L, Carter AC, Lu XM, Wu CI. Free-living human cells reconfigure their chromosomes in the evolution back to uni-cellularity. Elife, 2017, 6: e28070. |
| [79] | Yin SW, Zhong N, Agrawal S, Feng BR, Pradhan S, Jobalia NK, Vaziripour M, Poreddy SK, Kresty LA, Gillaspie EA, Dietz NE, Al-Refaie WB, Nandipati KC, Fu YS, Xia J. Single-cell genomic copy number evolution reveals frequent loss of the Y chromosome in esophageal adenocarcinoma. bioRxiv, 2025, doi: 10.1101/2025.09.14.676175. |
| [80] | Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv, 2019, 5(2): eaav2437. |
| [81] | Fröhling S, Döhner H. Chromosomal abnormalities in cancer. N Engl J Med, 2008, 359(7): 722-734. |
| [82] | Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB, Jefferies WA. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res, 2008, 68(23): 9601-9607. |
| [83] | Plage H, Ahlburg V, Hofbauer S, Furlano K, Weinberger S, Fendler A, Rossner F, Schallenberg S, Elezkurtaj S, Blessin NC, Lennartz M, Marx AH, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Koch S, Adamini N, Simon R, Sauter G, Zecha H, Weischenfeldt J, Klatte T, Minner S, Horst D, Schlomm T, Kluth M. Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers. BMC Cancer, 2025, 25(1): 677. |
| [84] | Guo XH, Dai XQ. A complex systems approach to mosaic loss of the Y chromosome. Geroscience, 2025, 47(1): 631-651. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
